Study led by Monroe Carell Jr. Children’s Hospital at Vanderbilt looks at international cohort with rare cancer - Vanderbilt Health News
This is a de-identified MRI scan from the REDCap database depicting numerous discrete lesions including fourth ventricle, thalamus, midbrain, cerebellum, brainstem and spine, highlighting the disseminated disease. (image courtesy/Michael Dewan, MD)
Print:
Print this article
By: Jessica Pasley
Pediatric-type, low-grade gliomas (PLGG) are the most common central nervous system (CNS) tumor in children, but in rare cases the tumors spread — known as disseminated pediatric low-grade gliomas (DPLGGs) — which leads to increased morbidity and mortality.
Researchers, led by Michael Dewan, MD, MSCI, compiled an international cohort of more than 260 DPLGG patients from 39 sites and 13 countries to study why low-grade brain tumors behave aggressively, as well as to identify the causative genetic alteration.
Study findings were recently published in Neuro-Oncology
“Our findings will help predict which children are at an elevated risk of developing disseminated low-grade gliomas as well as serve as a guide toward a more effective, personalized treatment,” said Dewan, associate professor of Neurological Surgery and Pediatrics at Monroe Carell Jr. Children’s Hospital at Vanderbilt and one of the study’s senior authors.
“Not all childhood brain tumors that look low-grade act the same,” he said. “This study expands our understanding of the clinical, pathologic and molecular features of this challenging disease. We found that when these tumors spread early or widely — especially in young children — outcomes are worse, but newer, targeted drugs work better than standard chemotherapy for many patients.”
Study findings inform prognosis and treatment decisions, particularly by supporting the earlier use of targeted, less-invasive therapies that may enhance survival and reduce treatment toxicity for children.
“This research improves our clinical and biological understanding of this rare disease, provides insights for improving patient care, and directs future clinical trials and basic science research,” said Dewan.
Related
Media Contacts
Jessica Pasley
(615) 322-4747
jessica.pasley@vumc.org
Popular in Cancer
March 10, 2025
VUMC to develop AI technology for therapeutic antibody discovery
April 18, 2024
New urine test has higher diagnostic accuracy for prostate cancer
April 7, 2021
Study revises understanding of cancer metabolism
Department of Neurological Surgery
Department of Pediatrics
Michael Dewan
Neuro-Oncology (journal)
Related Articles
October 27, 2022
Study to explore why some gliomas spread like cancerous tumors
Vanderbilt’s Michael Dewan, MD, MSCI, has received a grant from the Pediatric Brain Tumor Foundation to study why some low-grade gliomas, a type of non-cancerous brain or spine tumor, spread and behave like cancerous tumors.
By Nancy Humphrey
April 10, 2025
Study provides guidance on immunotherapy-related, chronic skin reactions
Researchers recommended long-term follow-up for patients by dermatologists familiar with cirAEs and consideration of corticosteroid-sparing treatment options.
By Tom Wilemon
September 26, 2025
VUMC’s global neurosurgery program provides education, training and impact through collaborations with partners across continents
The program seeks to both share and learn in its mission to enhance the neurological health of populations in low resourced settings.
By Evan Dorian
Loading Comments...